# KPT-330 Plus RICE for Relapsed/Refractory Aggressive B-Cell Lymphoma

> **NCT02471911** · PHASE1 · COMPLETED · sponsor: **Weill Medical College of Cornell University** · enrollment: 22 (actual)

## Conditions studied

- Diffuse Large B-Cell Lymphoma

## Interventions

- **DRUG:** KPT-330
- **DRUG:** Rituximab
- **DRUG:** Etoposide
- **DRUG:** Carboplatin
- **DRUG:** Ifosfamide
- **DRUG:** Dexamethasone

## Key facts

- **NCT ID:** NCT02471911
- **Lead sponsor:** Weill Medical College of Cornell University
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2015-12-11
- **Primary completion:** 2019-10-31
- **Final completion:** 2021-10-14
- **Target enrollment:** 22 (ACTUAL)
- **Last updated:** 2022-04-12

## Collaborators

- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02471911

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02471911, "KPT-330 Plus RICE for Relapsed/Refractory Aggressive B-Cell Lymphoma". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT02471911. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*